NCT03942068

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Evaluating the Efficacy and Safety of Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study was designed to evaluate the efficacy and safety of apatinib with albumin-bound paclitaxel in patients with platinum-resistant recurrent ovarian cancer.

Detailed description

The study is an open, one-arm, prospec will collect 35 patients with platinum-resistant recurrent ovarian cancer treated with apatinib with albumin-bound paclitaxel from 2019 to 2020 in Henan Cancer Hospital.Antiangiogenic treatments have been implicated to play a major role in ovarian cancer (OC). Apatinib, a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2), in combination with weekly paclitaxel, may improve clinical outcomes compared with apatinib or paclitaxel alone in patients with refractory or platinum-resistant ovarian cancer.

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
DRUG	albumin-bound paclitaxel	Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor
DRUG	Apatinib	a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)

Timeline

• Start date: 2019-09-01
• Primary completion: 2020-09-01
• Completion: 2020-12-30
• First posted: 2019-05-08
• Last updated: 2019-05-08